B of A Securities Maintains Neutral on Roivant Sciences, Raises Price Target to $12.5
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Neutral rating on Roivant Sciences while slightly raising the price target from $12 to $12.5.
September 11, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has maintained a Neutral rating on Roivant Sciences, indicating no strong buy or sell recommendation. However, the price target has been slightly increased from $12 to $12.5, suggesting a modestly positive outlook.
The Neutral rating suggests that the analyst does not see a strong reason to buy or sell the stock at this time. The slight increase in the price target to $12.5 indicates a modestly positive outlook, but not enough to change the overall rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100